Precursors and pathogenesis of ovarian carcinoma

Pathology

Volumn 45, Issue 3, 2013, Pages 229-242

  Lim, D ^a   Oliva, E ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Origin; Ovarian cancer; Pathogenesis; Precursors

Indexed keywords

EID: 84879674095     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835f2264     Document Type: Article

References (186)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994; 73: 1859-64.
3. Powell DE, Puls L, van Nagell J Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum Pathol 1992; 23: 846-7.
4. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47: 53-7.
5. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72: 437-42.
6. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-60.
7. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8.
8. Cho KR, Shih Ie M. Ovarian cancer. Ann Rev Pathol 2009; 4: 287-313.
9. Senturk E, Cohen S, Dottino PR, et al. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecol Oncol 2010; 119: 376-83.
10. Maeda D, Ota S, Takazawa Y, et al. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Archiv 2010; 457: 597-608.
11. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004; 191: 718-32.
12. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-6.
13. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-16.
14. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-5.
15. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
16. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336-40.
17. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-8.
18. Singer G, Shih Ie M, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003; 22: 37-41.
19. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-24.
20. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008; 27: 161-74.
21. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-82.
22. Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian lowand high-grade serous neoplasms. Histopathology 2013; 62: 44-58.
23. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-43.
24. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 2010; 22: 462-72.
25. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331-45.
26. Alvarez AA, Moore WF, Robboy SJ, et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol 2001; 80: 201-6.
27. Haas CJ, Diebold J, Hirschmann A, et al. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Archiv 1999; 434: 117-20.
28. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-7.
29. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-6.
30. Ho CL, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-8.
31. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 2002; 33: 47-59.
32. May T, Virtanen C, Sharma M, et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 2010; 117: 9-17.
33. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-12.
34. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38: 87-95.
35. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008; 9: 1191-7.
36. Lauchlan SC. The secondary Mullerian system. Obstet Gynecol Surv 1972; 27: 133-46.
37. Altaras MM, Jaffe R, Corduba M, et al. Primary paraovarian cystadenocarcinoma: clinical and management aspects and literature review. Gynecol Oncol 1990; 38: 268-72.
38. De Areia AL, Frutuoso C, Amaral N, et al. Paraovarian tumor of borderline malignancy-a case report. Int J Gynecol Cancer 2004; 14: 680-2.
39. Kurman RJ, Vang R, Junge J, et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011; 35: 1605-14.
40. Li J, Abushahin N, Pang S, et al. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol 2011; 24: 1488-99.
41. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-1.
42. Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006; 12: 5944-50.
43. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in lowgrade and high-grade carcinomas. Cancer Res 2009; 69: 4036-42.
44. Salani R, Kurman RJ, Giuntoli R 2nd et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008; 18: 487-91.
45. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004; 112: 14-25.
46. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J, editor. Atlas of Tumor Pathology. 3rd ed. Washington: Armed Forces Institute of Pathology, 1998, 125-6.
47. Tavassoli F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Breast and Female Genital Organs. Lyon: IARC Press, 2003.
48. Mhawech P, Kinkel K, Vlastos G, et al. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. Int J Gynecol Pathol 2002; 21: 401-6.
49. Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol 2003; 109: 97-101.
50. Russell P. The pathological assessment of ovarian neoplasms. I: Introduction to the common 'epithelial' tumours and analysis of benign 'epithelial' tumours. Pathology 1979; 11: 5-26.
51. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20: 133-9.
52. Nezhat F, Cohen C, Rahaman J, et al. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002; 94: 2935-40.
53. Horiuchi A, Itoh K, Shimizu M, et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 2003; 88: 309-17.
54. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009; 28: 308-15.
55. Tang S, Onuma K, Deb P, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 2012; 31: 103-10.
56. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-90.
57. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 1327-34.
58. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64.
59. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9.
60. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-6.
61. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003; 88: S8-10.
62. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16.
63. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-10.
64. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90: 841-5.
65. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21: 407-11.
66. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26: 4160-5.
67. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol 2010; 222: 110-6.
68. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma- evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-6.
69. Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-55.
70. Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 2010; 34: 18-26.
71. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 6116-26.
72. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010; 29: 310-4.
73. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011; 35: 1766- 75.
74. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012; 31: 243-53.
75. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9.
76. Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010; 17: 293-302.
77. Beral V, Bull D, Green J, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-10.
78. Risch HA, Weiss NS, Lyon JL, et al. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117: 128- 39.
79. Garg K, Park KJ, Soslow RA. Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases. Int J Gynecol Pathol 2012; 31: 423-8.
80. Silva EG, Tornos CS, Malpica A, et al. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Mod Pathol 1997; 10: 663-7.
81. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
82. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008; 110: 408-17.
83. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Frontiers Biosci 2011; 3: 625-34.
84. Carlson J, Roh MH, Chang MC, et al. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol 2008; 14: 352-65.
85. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-93.
86. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor ('p53 signature') in women with inherited BRCA mutations. Gynecol Oncol 2008; 111: 226-32.
87. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22: 1133-8.
88. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-73.
89. Fukunaga M, Nomura K, Ishikawa E, et al. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997; 30: 249-55.
90. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol 1990; 75: 1023-8.
91. Moll UM, Chumas JC, Chalas E, et al. Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol 1990; 75: 537-9.
92. Sainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996; 60: 238-44.
93. Aure JC, Hoeg K, Kolstad P. Carcinoma of the ovary and endometriosis. Acta Obstet Gynecol Scand 1971; 50: 63-7.
94. Jimbo H, Yoshikawa H, Onda T, et al. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet 1997; 59: 245-50.
95. Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77: 298-304.
96. Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol 1980; 23: 951-63.
97. Bell DA, Scully RE. Atypical and borderline endometrioid adenofibromas of the ovary. A report of 27 cases. Am J Surg Pathol 1985; 9: 205-14.
98. Snyder RR, Norris HJ, Tavassoli F. Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol 1988; 12: 661-71.
99. Bulun SE. Endometriosis. N Engl J Med 2009; 360: 268-79.
100. Kashima K, Ishimaru T, Okamura H, et al. Familial risk among Japanese patients with endometriosis. Int J Gynaecol Obstet 2004; 84: 61-4.
101. Treloar S, Hadfield R, Montgomery G, et al. The International Endogene Study: a collection of families for genetic research in endometriosis. Fertil Steril 2002; 78: 679-85.
102. Treloar SA, Wicks J, Nyholt DR, et al. Genomewide linkage study in 1, 176 affected sister pair families identifies a significant susceptibility locus for endometriosis on chromosome 10q26. Am J Hum Genet 2005; 77: 365-76.
103. Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. Gynecol Obstet Invest 2000; 50 (Suppl 1): 44-50.
104. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60: 7052-6.
105. Teague EM, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update 2010; 16: 142-65.
106. Defrere S, Lousse JC, Gonzalez-Ramos R, et al. Potential involvement of iron in the pathogenesis of peritoneal endometriosis. Mol Hum Reprod 2008; 14: 377-85.
107. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-71.
108. Kobayashi H, Yamada Y, Kanayama S, et al. The role of iron in the pathogenesis of endometriosis. Gynecol Endocrinol 2009; 25: 39-52.
109. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012; 124: 164-9.
110. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189: 280-94.
111. Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril 2002; 77: 861-70.
112. Wei JJ, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol 2011; 30: 553-68.
113. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008; 14: 32-40.
114. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomark Prev 1996; 5: 933-5.
115. Vercellini P, Parazzini F, Bolis G, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993; 169: 181-2.
116. Ali-Fehmi R, Khalifeh I, Bandyopadhyay S, et al. Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis. Int J Gynecol Pathol 2006; 25: 223-9.
117. Chalas E, Chumas J, Barbieri R, et al. Nucleolar organizer regions in endometriosis, atypical endometriosis, and clear cell and endometrioid carcinomas. Gynecol Oncol 1991; 40: 260-3.
118. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979; 53: 318-23.
119. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol 1988; 19: 1080-4.
120. Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol 1999; 155: 1047-50.
121. Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18: 349-71.
122. Ballouk F, Ross JS, Wolf BC. Ovarian endometriotic cysts. An analysis of cytologic atypia and DNA ploidy patterns. Am J Clin Pathol 1994; 102: 415-9.
123. Prefumo F, Todeschini F, Fulcheri E, et al. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 2002; 84: 280-4.
124. Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1Aassociated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 2012; 22: 9-14.
125. Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002; 102: 398-406.
126. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095-7.
127. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006; 119: 556-62.
128. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-8.
129. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-81.
130. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001; 10: 116-22.
131. Cuatrecasas M, Erill N, Musulen E, et al. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998; 82: 1088-95.
132. Oliva E, Sarrio D, Brachtel EF, et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 2006; 208: 708-13.
133. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009; 33: 1157-63.
134. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/betacatenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11: 321-33.
135. Anglesio MS, Carey MS, Kobel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121: 407-15.
136. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-9.
137. Veras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 2009; 33: 844-53.
138. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
139. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
140. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-68.
141. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310-5.
142. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012; 5: 642-50.
143. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-601.
144. Lee S, Garner EI, Welch WR, et al. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 2007; 106: 311-7.
145. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; 29: 1741-52.
146. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
147. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
148. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. Public Library Sci Med 2008; 5: e232.
149. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191-8.
150. Skirnisdottir I, Seidal T, Karlsson MG, et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005; 26: 177-83.
151. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99: 653-8.
152. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-706.
153. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010; 29: 203-11.
154. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-4.
155. Cariker M, Dockerty M. Mucinous cystadenomas and mucinous cystadenocarcinomas of the ovary; a clinical and pathological study of 355 cases. Cancer 1954; 7: 302-10.
156. Woodruff JD, Bie LS, Sherman RJ. Mucinous tumors of the ovary. Obstet Gynecol 1960; 16: 699-712.
157. Hertig AT, Gore H. Atlas of Tumor Pathology. Tumors of the Female Sex Organs. Part 3, Tumors of the Ovary and Fallopian Tube. Section IX, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology, 1961.
158. Resta L, Russo S, Colucci GA, et al. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993; 82: 181-6.
159. Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88: 1810-20.
160. Towers RP. A note on the origin of the pseudomucinous cystadenoma of the ovary. J Obstet Gynaecol Br Emp 1956; 63: 253-4.
161. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer 1988; 61: 340-8.
162. Wu CH, Mao TL, Vang R, et al. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol 2012; 31: 297-303.
163. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998; 22: 1449-62.
164. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000; 24: 1447-64.
165. Nomura K, Aizawa S. A histogenetic consideration of ovarian mucinous tumors based on an analysis of lesions associated with teratomas or Brenner tumors. Pathol Int 1997; 47: 862-5.
166. Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 2008; 132: 1753-60.
167. Pejovic T, Burki N, Odunsi K, et al. Well-differentiated mucinous carcinoma of the ovary and a coexisting Brenner tumor both exhibit amplification of 12q14-21 by comparative genomic hybridization. Gynecol Oncol 1999; 74: 134-7.
168. Caduff RF, Svoboda-Newman SM, Ferguson AW, et al. Comparison of mutations of Ki-ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999; 23: 323-8.
169. Enomoto T, Weghorst CM, Inoue M, et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777-85.
170. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-81.
171. Ichikawa Y, Nishida M, Suzuki H, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994; 54: 33-5.
172. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-92.
173. Kim KR, Choi J, Hwang JE, et al. Endocervical-like (Mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology 2010; 57: 587-96.
174. Anglesio M, Kommoss S, Tolcher M, et al. Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 18% of carcinomas. J Pathol 2013; 229: 111-20.
175. Yan B, Choo SN, Mulyadi P, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 2011; 64: 1097-101.
176. Gupta M, Gonzalez JL, Lefferts LA, et al. Primary ovarian mucinous tumors (OMT) lack loss of MLH-1 and MGMT and are characterized by KRAS mutations and aberrant p53 expression when they progress to carcinoma. Mod Pathol 2009; 22: 216A.
177. Cuatrecasas M, Catasus L, Palacios J, et al. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol 2009; 33: 556-67.
178. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with
179. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Archiv 2001; 438: 181-91.
180. Ali RH, Seidman JD, Luk M, et al. Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. Int J Gynecol Pathol 2012; 31: 499-506.
181. Costa MJ, Hansen C, Dickerman A, et al. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol 1998; 109: 173-80.
182. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 2004; 28: 453-63.
183. Silva EG, Robey-Cafferty SS, Smith TL, et al. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Surg Pathol 1990; 93: 457-65.
184. Shevchuk MM, Fenoglio CM, Richart RM. Histogenesis of Brenner tumors, II: histochemistry and CEA. Cancer 1980; 46: 2617-22.
185. Waxman M. Pure and mixed Brenner tumors of the ovary: clinicopathologic and histogenetic observations. Cancer 1979; 43: 1830-9.
186. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113: 775-82.